Frequency Therapeutics, Inc.

NasdaqCM:FREQ Stock Report

Market Cap: US$547.3m

Frequency Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

David Lucchino

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage19.9%
CEO tenure9yrs
CEO ownership1.7%
Management average tenureno data
Board average tenure7.2yrs

Recent management updates

Recent updates

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Jan 01
Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Jan 19
Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Aug 18
Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Jul 31
Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Frequency Therapeutics (FREQ) Investor Presentation - Slideshow

Jun 18

Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout

Apr 21

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Apr 04
Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Mar 15
We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Jan 22
If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Dec 27
Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Frequency Therapeutics to host investor event in early January next year

Dec 18

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

Dec 10
How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 19
Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Frequency Therapeutics EPS beats by $0.16, beats on revenue

Nov 16

Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results

Nov 09

CEO Compensation Analysis

How has David Lucchino's remuneration changed compared to Frequency Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$67m

Mar 31 2023n/an/a

-US$78m

Dec 31 2022US$3mUS$630k

-US$82m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$91m

Mar 31 2022n/an/a

-US$88m

Dec 31 2021US$6mUS$600k

-US$85m

Sep 30 2021n/an/a

-US$73m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020US$5mUS$551k

-US$27m

Sep 30 2020n/an/a

-US$22m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$19m

Dec 31 2019US$7mUS$442k

-US$20m

Sep 30 2019n/an/a

-US$20m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$744kUS$367k

-US$19m

Compensation vs Market: David's total compensation ($USD3.16M) is above average for companies of similar size in the US market ($USD2.23M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Lucchino (53 yo)

9yrs

Tenure

US$3,159,278

Compensation

Mr. David L. Lucchino is a Co-Founder of Frequency Therapeutics, Inc. and has been its Chief Executive Officer and President since November 2014. Mr. Lucchino served as Treasurer and Secretary of Frequency...

Board Members

NamePositionTenureCompensationOwnership
David Lucchino
Co-Founder9yrsUS$3.16m1.73%
$ 9.5m
John LaMattina
Senior Advisor & Member of PCA Regenerative Medicine Advisory Board6.7yrsno datano data
Timothy Barberich
Independent Vice Chairman7.2yrsUS$104.32k0.22%
$ 1.2m
Robert Langer
Independent Director & Member of PCA Regenerative Medicine Advisory Board7.2yrsUS$133.32k0.66%
$ 3.6m
Cynthia Feldmann
Independent Director3.2yrsUS$92.82k0%
$ 0
Kenneth Anderson
Member of PCA Regenerative Medicine Advisory Boardno datano datano data
Ralph Mazitschek
Member of PCA Regenerative Medicine Advisory Boardno datano datano data
Jeffrey Karp
Member of PCA Regenerative Medicine Advisory Boardno datano datano data
Stephen Haggarty
Member of PCA Regenerative Medicine Advisory Boardno datano datano data
Xiaolei Yin
Member of PCA Regenerative Medicine Advisory Boardno datano datano data
Daniel Lee
Member of Clinical Advisory Boardno datano datano data
Joni Doherty
Member of Clinical Advisory Boardno datano datano data

7.2yrs

Average Tenure

72.5yo

Average Age

Experienced Board: FREQ's board of directors are considered experienced (7.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/05 11:23
End of Day Share Price 2023/11/03 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Frequency Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Mayank MamtaniB. Riley Securities, Inc.
Daniil GataulinChardan Capital Markets, LLC